Literature DB >> 16786126

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.

Axel S Merseburger1, Jörg Hennenlotter, Perikles Simon, Carolin C Müller, Ursula Kühs, Ruth Knüchel-Clarke, Judd W Moul, Arnulf Stenzl, Markus A Kuczyk.   

Abstract

In order to evaluate the molecular heterogeneity of prostate cancer, this study examined the expression of Akt-pathway related parameters within the cancerous prostate gland. PTEN, p-Akt and p27kip1 are known to be altered in prostate cancer. Tissue samples from malignant, tumor adjacent benign and benign areas of 25 whole mounted prostate cancer specimens were processed to 583 tissue microarray cores. Immunohistochemically determined biomarker expression was correlated to the different localizations. p-Akt and p27kip1 showed increased staining in malignant tissue compared to the respective benign tissue (p < 0.01 and p < 0.05). The adjacent but histologically benign tissue had increased levels (p < 0.05 and p < 0.01), whereas no significant difference was found between the adjacent and malignant regions. A highly significant correlation of p-Akt and p27kip1 in benign tissue (p < 0.001) was lost in the adjacent areas and in the malignant tissue (p = 0.054 and p = 0.12). In tendency, PTEN expression was decreased in the malignant regions and revealed the highest staining in the adjacent zone. According to the results obtained, the expression of p-Akt and p27kip1 was increased in both the adjacent microscopically benign tissue as well as the primary tumors when compared with the histologically benign tissue specimens that served as biological control. The increased expression of PTEN indicates its regulatory function in the initial steps of a deteriorated cell cycle control as well as uncontrolled cellular proliferation, for example, which seem to be present in the normal prostatic tissue surrounding the primary malignant lesion. The addition of molecular markers to a 'classical' histopathological approach might contribute to an enhanced sensitivity of analytical approaches aimed at the detection of malignant or premalignant lesions within prostatic biopsies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786126

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

Review 2.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

3.  Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue.

Authors:  F Mittag; J Hennenlotter; L Minkley; I Ipach; D Schilling; M Scharpf; A Stenzl; U Leichtle; T Kluba
Journal:  Clin Exp Metastasis       Date:  2011-12-01       Impact factor: 5.150

4.  Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma.

Authors:  B Amend; J Hennenlotter; M Scharpf; S Kruck; U Kuehs; E Senger; A S Merseburger; M A Kuczyk; K D Sievert; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2011-08-07       Impact factor: 4.226

5.  Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

Authors:  Z Wu; D Gioeli; M Conaway; M J Weber; D Theodorescu
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104

6.  Fibronectin 1 protein expression in clear cell renal cell carcinoma.

Authors:  S Steffens; A J Schrader; Gesa Vetter; H Eggers; H Blasig; J Becker; M A Kuczyk; J Serth
Journal:  Oncol Lett       Date:  2012-01-12       Impact factor: 2.967

7.  [The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy].

Authors:  K-D Sievert; A G Anastasiadis; J Hennenlotter; D Schilling; A S Merseburger; U Nagele; M P Lichy; H-P Schlemmer; A Ulmer; U Vogel; K Sotlar; M Kuczyk; A Stenzl
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

8.  Caveolin 1 protein expression in renal cell carcinoma predicts survival.

Authors:  Sandra Steffens; Andres J Schrader; Hanna Blasig; Gesa Vetter; Hendrik Eggers; Wolfgang Tränkenschuh; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Urol       Date:  2011-12-07       Impact factor: 2.264

9.  Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.

Authors:  Murielle Mimeault; Sonny L Johansson; Surinder K Batra
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

10.  Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer.

Authors:  Martin Heni; Jörg Hennenlotter; Marcus Scharpf; Stefan Z Lutz; Christian Schwentner; Tilman Todenhöfer; David Schilling; Ursula Kühs; Valentina Gerber; Fausto Machicao; Harald Staiger; Hans-Ulrich Häring; Arnulf Stenzl
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.